Physician profile
Michael E Ritchie
NPI 1386717437
$4,997.73
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,935 · 2020: $281 · 2021: $263 · 2022: $1,292 · 2023: $507 · 2024: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,894.16 | 2019-2020 | |
| Abbott Laboratories | $1,360.66 | 2022-2024 | Amplatzer Amulet, Id Now Instrument, Xience Skypoint |
| Novartis Pharmaceuticals Corporation | $390.06 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $255.18 | 2019-2024 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $119.81 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $107.06 | 2019-2024 | Repatha |
| Biotronik INC. | $98.08 | 2021-2023 | Nhancer Rx, Orsiro Mission |
| Merck Sharp & Dohme LLC | $89.32 | 2021-2024 | Verquvo, Winrevair |
| Medtronic, INC. | $75.18 | 2022-2024 | Onyx Frontier |
| Bayer Healthcare Pharmaceuticals INC. | $71.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $64.08 | 2019-2021 | |
| Pfizer INC. | $60.76 | 2021-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $52.82 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $49.30 | 2020-2021 | |
| Abiomed | $48.25 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.93 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $43.04 | 2020-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $38.43 | 2023-2024 | Amvuttra |
| Mylan Specialty L.P. | $25.82 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $15.00 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $14.50 | 2021 | |
| Boston Scientific Corporation | $13.31 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.21 | 2019 | |
| Grifols USA, LLC | $11.95 | 2021 | |
| Livanova USA, INC. | $11.40 | 2021 | |
| United Therapeutics Corporation | $9.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ritchie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.